Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733949 | 1.00 | — | — | |
| SCHEMBL21483911 | 1.00 | TSHR (0.33) | TSHR | |
| SCHEMBL3679955 | 1.00 | TSHR (0.33) | TSHR | |
| SCHEMBL20210411 | 1.00 | — | — | |
| SCHEMBL21483963 | 1.00 | TSHR (0.33) | TSHR | |
| SCHEMBL2734269 | 1.00 | TSHR (0.33) | TSHR | |
| SCHEMBL2734647 | 1.00 | — | — | |
| SCHEMBL2733745 | 0.96 | — | — | |
| SCHEMBL4092325 | 0.85 | TSHR (0.44) | TSHR | |
| SCHEMBL1318970 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380673-B | Dialkoxy alkenyl alkoxy methyl ether compound and method for preparing terminal conjugated alkadiene aldehyde compound from same | 信越化学工业株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-110386855-B | 1-halodiene and process for preparing it and (9E, 111Z) -9, 11-hexadecadienylacetate | 信越化学工业株式会社 | 2023-03-28 | — | — | CN | disclosed |
| CN-114380673-A | Dialkoxyalkenylalkoxymethyl ether compounds and process for producing conjugated alkadienal compounds from the same | 信越化学工业株式会社 | 2022-04-22 | — | — | CN | disclosed |
| CN-114380689-A | Haloalkenylalkoxymethyl ethers and processes for preparing terminally conjugated alkadien-1-yl acetates and alkadien-1-ols therefrom | 信越化学工业株式会社 | 2022-04-22 | — | — | CN | disclosed |
| EP-3556742-B1 | 1-HALOALKADIENE AND PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9E,11Z)-9,11-HEXADECADIENYL ACETATE | SHINETSU CHEMICAL CO (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-10737999-B2 | 1-haloalkadiene and a process for preparing the same and a process for preparing (9e, 11z)-9,11-hexadecadienyl acetate | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-11 | — | — | US | disclosed |
| US-20190322614-A1 | 1-HALOALKADIENE AND A PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9e, 11z)-9,11-HEXADECADIENYL ACETATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-3556742-A1 | 1-HALOALKADIENE AND PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9E,11Z)-9,11-HEXADECADIENYL ACETATE | Shin-Etsu Chemical Co., Ltd. (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20070270521-A1 | Transition metal compound, polymerization-initiator system comprising the same, and process for producing polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| CN-101024659-A | Transition metal compound, polymerization initiator system including same and polymer production method | SUMITOMO CHEMICAL CO (JP) | 2007-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270521-A1 | Transition metal compound, polymerization-initiator system comprising the same, and process for producing polymer | CARM1, CPN1, CCNT1 | TSHR 4291/4885 |
| US-20190322614-A1 | 1-HALOALKADIENE AND A PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9e, 11z)-9,11-HEXADECADIENYL ACETATE | CYP8B1, HDHD5, HACL2 | TSHR 2265/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | TSHR 2243/4885 |
| US-10737999-B2 | 1-haloalkadiene and a process for preparing the same and a process for preparing (9e, 11z)-9,11-hexadecadienyl acetate | CYP8B1, HDHD5, HACL2 | TSHR 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.